Bio Blast Pharma Ltd(NASDAQ:ORPN) announced the earnings results for Fiscal Year 2016 and Q3. The results came in during Pre-market on Nov 29, 2016. Earnings per share were $-0.28. The reported EPS was below estimates by $-0.06 or NaN%. Analysts had estimated an EPS of $-0.22.
Bio Blast Pharma Ltd (ORPN) shares turned negative on Tuesdays trading session with the shares closing down -0.19 points or -11.88% at a volume of 1,18,997. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $1.6. The peak price level was also seen at $1.6 while the days lowest was $1.3. Finally the shares closed at $1.41. The 52-week high of the shares is $7.95 while the 52-week low is $1.3. According to the latest information available, the market cap of the company is $23 M.
Bio Blast Pharma Ltd. (BioBlast) is a development-stage biopharmaceutical company. The Company is focused on the identification licensing acquisition development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. The Company is advancing its Cabaletta platform product candidates through clinical development and advancing its other product candidates BB-FA BB-OTC and BBrm1 as well as its other early stage research projects through preclinical development. The Company’s three principal product candidate platforms include Protein Stabilizing Platform Read-through Platform and Mitochondrial Protein Replacement Platform. The Company is developing Cabaletta for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD); spinocerebellar ataxia type 3 (SCA3) and Spinobulbar Muscular Atrophy (SBMA). It is conducting preclinical studies of BBrm1 for the treatment of Spinal Muscular Atrophy (SMA).